trending Market Intelligence /marketintelligence/en/news-insights/trending/3hihl8mxasb1n3dvguj-gg2 content esgSubNav
In This List

US FDA to decide on Bristol-Myers' cancer drug combo in July

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


US FDA to decide on Bristol-Myers' cancer drug combo in July

The U.S. Food and Drug Administration granted priority review to Bristol-Myers Squibb Co.'s supplemental biologics license application to market the Opdivo and Yervoy combination for colorectal cancer.

Bristol is seeking approval for the combination's use in treating adults with microsatellite instability-high or DNA mismatch repair deficient colorectal cancer that has spread and progressed after receiving prior chemotherapy treatments.

The action date for the application is July 10.

The combination received the FDA's breakthrough therapy designation in February to expedite development.

Bristol's supplemental application is backed by the results of the ongoing phase 2 CheckMate-142 trial studying the combination in previously treated patients.